Put companies on watchlist
Edison Investment Research Limited
ISIN: GB00BN455J50
WKN: A3EJG1
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Edison Investment Research Limited · ISIN: GB00BN455J50 · EQS - Company News (2 News)
Country: Great Britain · Primary market: United Kingdom · EQS NID: 2047197
09 December 2024 01:17PM

Edison issues report on Worldwide Healthcare Trust (WWH)


Edison Investment Research Limited
Edison issues report on Worldwide Healthcare Trust (WWH)

09-Dec-2024 / 12:17 GMT/BST
The issuer is solely responsible for the content of this announcement.


 

London, UK, 9 December 2024

 

Edison issues report on Worldwide Healthcare Trust (WWH)

Edison issues report on Worldwide Healthcare Trust (LSE: WWH).

Worldwide Healthcare Trust (WWH) will be celebrating its 30th birthday in 2025 and, despite more recent underperformance, the trust has served its shareholders well over the long term. Its NAV and share price total returns of +4,770% and +4,181% respectively, since launch in April 1995 to the end of September 2024, are considerably ahead of the benchmark’s +2,438% total return. Co-managers, Sven Borho and Trevor Polischuk, at global healthcare specialist OrbiMed, remain bullish on the industry outlook. They believe that the sector is poised for a catch-up in relative performance, having uncharacteristically lagged the performance of the broad US market in recent quarters. The managers point to favourable healthcare industry fundamentals, which include a high level of innovation, a supportive regulatory environment and robust levels of M&A activity. This is partly due to an upcoming patent cliff and senior executives at major pharma companies have been vocal about the need to replenish their product lines as their key drugs go off patent.

Click here to read the full report.

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

enquiries@edisongroup.com

Connect with Edison on:

 

LinkedIn www.linkedin.com/company/edison-group-/

X  www.x.com/edison_inv_res

YouTube www.youtube.com/edisonitv



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

2047197  09-Dec-2024 

fncls.ssp?fn=show_t_gif&application_id=2047197&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Edison Investment Research Limited
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.